Ceva Completes Deal to Acquire Portfolio of Merial Swine and Cattle Vaccines and Nonsteroidal Anti-inflammatories from Boehringer Ingelheim

Food and Healthcare Press Releases Friday January 20, 2017 10:34
LIBOURNE, France--20 Jan--PRNewswire/InfoQuest

Ceva Sante Animale today completed the acquisition of a diversified portfolio of products, including swine and cattle vaccines and multi-species nonsteroidal anti-inflammatories from Boehringer Ingelheim following its acquisition of Merial Animal Health.

All the products will be immediately available through local Ceva companies or its distributors, with no interruption of supply.
Ceva has been consistently one of the fastest growing top 10 veterinary businesses in the last decade, investing heavily in the development of vaccines, as part of its global preventative health strategy.
Commenting on the deal, Ceva Chairman & CEO Dr. Marc Prikazsky said:

"We are delighted to acquire this range of products and strong pipeline of R&D assets.   The knowhow behind these products dates from Pasteur, Rhone-Merieux, Merial and now as Ceva we are conscious that we have a responsibility to maintain this strong veterinary scientific tradition.   Our customers can be assured that we will continue to invest to develop the products of both today and tomorrow."

ABOUT CEVA SANTE ANIMALE

Ceva Sante Animale was founded in 1999 and is a global veterinary health company, focused on research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Its headquarters are in Libourne (Gironde). Ceva Chairman and CEO is Marc Prikazsky.

Website: http://www.ceva.com
PRESS CONTACT
Martin Mitchell
Communication Director
+33-05-57-55-40-80
martin.mitchell@ceva.com
Company: Davidson Ryan Dore
Lawrence Dore
Lawrence.dore@drdpartnership.com
Phone: +44(0)207-520-9218
Source: Ceva Sante Animale

Latest Press Release

New Blood for the world 9th year - Bangkok Hospital Pattaya

Bangkok Hospital Pattaya in cooperation with Queen Savang Vadhana Memorial Hospital (Somdej Pra Boromrajthevi na Sriracha) and the Thai Red Cross Society, have combined for another Blood Donation project. On Thursday 23rd March 2017 from 9.30 a.m....

Fiasp(R)Black Triangle Drug, a new, ultra-fast acting mealtime insulin is available for the treatment of diabetes in adults

Today, Novo Nordisk announced that Fiasp(R), a new, fast-acting mealtime insulin for the treatment of diabetes in adults, has been launched in Canada, following the recent marketing authorisation from Health Canada on 6 January 2017. Fiasp(R) is insulin...

FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma

- Only FDA-approved treatment for metastatic Merkel cell carcinoma, a rare and aggressive skin cancer - First indication for BAVENCIO, a human anti-PD-L1 antibody Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration...

Rajanukul Institute Honored for Pioneering Global Health Work with First-ever Golisano Global Health Leadership Award

The Golisano Foundation and Special Olympics, the largest public health organization for people with intellectual disabilities (ID), honored the Rajanukul Institute, Ministry of Public Health, Thailand in Bangkok, Thailand for launching a national health...

Truth or Myth? Global Survey for World Oral Health Day Exposes the Truth About our Oral Health Habits

Today on World Oral Health Day , FDI World Dental Federation is myth busting what people around the world believe to be good oral health practices, encouraging them to become better informed and take action. Oral health is integral to our general health...

Related Topics